The development of novel therapiesfor bevacizumab-induced brain tumor invasion
Project/Area Number |
26670644
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Neurosurgery
|
Research Institution | Okayama University |
Principal Investigator |
Date Isao 岡山大学, 医歯薬学総合研究科, 教授 (70236785)
|
Co-Investigator(Kenkyū-buntansha) |
黒住 和彦 岡山大学, 大学病院, 講師 (20509608)
杉生 憲志 岡山大学, 大学病院, 准教授 (40325105)
安原 隆雄 岡山大学, 医歯薬学総合研究科, 講師 (50457214)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | Bevacizumab / Integrin / Molecular targeted drug / invasion / glioma |
Outline of Final Research Achievements |
Glioblastoma is known to secrete high levels of vascular endothelial growth factor (VEGF). Clinical studies with bevacizumab, a monoclonal antibody to VEGF, have demonstrated convincing therapeutic benefits in glioblastoma patients. However, its induction of invasive proliferation has also been reported. We examined the effects of treatment with cilengitide, an integrin inhibitor, on bevacizumab-induced invasive changes in glioma. U87ΔEGFR cells were stereotactically injected into the brain of nude mice or rats. When the rats were treated with a combination of bevacizumab and cilengitide, the depth of tumor invasion was significantly less than with only bevacizumab. Pathway analysis demonstrated the inhibition of invasion associated genes such as the integrin-mediated cell adhesion pathway in the combination group. This study showed that the combination of bevacizumab with cilengitide exerted its anti-invasive effect.
|
Report
(4 results)
Research Products
(168 results)
-
-
-
-
-
[Journal Article] Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.2016
Author(s)
Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, Hashida S, Miyata-Takata T, Watanabe M, Suzawa K, Soh J, Youyi C, Sato H, Namba K, Torigoe H, Tsukuda K, Yoshino T, Miyoshi S, Toyooka S.
-
Journal Title
Sci Rep
Volume: 6
Issue: 1
Pages: 33319-33319
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
[Journal Article] Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma2015
Author(s)
Onishi M , Ichikawa T , Kurozumi K , Inoue S , Maruo T , Otani Y , Fujii K , Ishida J , Shimazu Y , Yoshida K , Michiue H , Chiocca EA , Date I
-
Journal Title
Brain Tumor Patholog
Volume: -
Issue: 3
Pages: 184-194
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma.2014
Author(s)
Shimazu Y, Kurozumi K, Ichikawa T, Fujii K, Onishi M, Ishida J, Oka T, Watanabe M, Nasu Y, Kumon H, Date I.
-
Journal Title
Gene Ther
Volume: 22
Issue: 2
Pages: 146-154
DOI
Related Report
Peer Reviewed
-
[Journal Article] Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.2014
Author(s)
Ichikawa T, Kurozumi K, Michiue H, Ishida J, Maeda Y, Kondo E, Kawasaki A, Date I.
-
Journal Title
Clin Neurol Neurosurg
Volume: 127
Pages: 106-11
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 視床グリオーマの治療成績2016
Author(s)
黒住和彦、亀田雅博、石田穣治、市川智継、伊達 勲
Organizer
第34回日本脳腫瘍学会学術集会
Place of Presentation
甲府富士屋ホテル(甲府市)
Year and Date
2016-12-05
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy2016
Author(s)
Oka T , Kurozumi K , Shimazu Y , Ichikawa T , Ishida J , Otani Y , Shimizu T , Tomita Y , Sakaguchi M , Watanabe M , Nasu Y , Kumon H , Date I
Organizer
第22回日本遺伝子細胞治療学会
Place of Presentation
虎ノ門ヒルズフォーラム(東京都港区)
Year and Date
2016-07-29
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] A super gene expression system enhances the antitumor effects of adenovirus -Mediated REIC/Dkk-3 gene therapy2016
Author(s)
Kurozumi K , Oka T , Shimazu Y , Ichikawa T , Shimizu T , Ishida J , Otani Y , Sakaguchi M , Watanabe M , Nasu Y , Kumon H , Date I
Organizer
21st International Conference on Brain Tumor Research and Therapy
Place of Presentation
万国津梁館(名護市)
Year and Date
2016-04-11
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy2015
Author(s)
Oka T , Kurozumi K , Ichikawa T , Shimazu Y , Otani Y , Shimizu T , Sakaguchi M , Watanabe M , Nasu Y , Kumon H , Date I
Organizer
第21回日本遺伝子治療学会学術集会
Place of Presentation
大阪国際会議場(大阪)
Year and Date
2015-07-25
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] High survival rate in pediatric medulloblastoma with postoperative combined chemotherapy and reduced craniospinal radiotherapy (English Session)2014
Author(s)
Ichikawa T , Shimizu T , Kurozumi K , Otani Y , Shimada A , Washio K , Nishiuchi R , Oda M , Katsui K , Yanai H , Date I
Organizer
第56回日本小児血液・がん学会学術集会
Place of Presentation
岡山
Year and Date
2014-11-28
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Angiogenesis/invasion phenotypic shift regulated by Annexin A2 in malignant glioma2014
Author(s)
Otani Y , Ichikawa T , Onishi M , Kurozumi K , Inoue S , Maruo T , Ishida J , Shimazu Y , Oka T , Shimizu T , Michiue H , Chiocca EA , Date I
Organizer
11th Meeting of Asian Society for Neuro-Oncology
Place of Presentation
Istanbul, Turkey
Year and Date
2014-09-11
Related Report
-
[Presentation] High response rate to methotrexate-based multiagent chemotherapy (M-CHOP) for primary central nervous system lymphoma2014
Author(s)
Ichikawa T , Kurozumi K, Michiue H , Ishida J , Shimazu Y , Oka T , Otani Y , Shimizu T , Maeda Y , Kondo E , Kawasaki A Date I
Organizer
11th Meeting of Asian Society for Neuro-Oncology
Place of Presentation
Istanbul, Turkey
Year and Date
2014-09-11
Related Report
-
[Presentation] Integrin inhibitor suppresses bevacizumab-induced glioma invasion2014
Author(s)
Shimizu T, Ishida J, Onishi M, Kurozumi K, Ichikawa T, Fujii K, Shimazu Y, Oka T, Otani Y, Date I
Organizer
11th Meeting of Asian Society for Neuro-Oncology
Place of Presentation
Istanbul, Turkey
Year and Date
2014-09-11
Related Report
-
-